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Reversine inhibits Colon Carcinoma 
Cell Migration by Targeting JNK1
Mohamed Jemaà  1,2, Yasmin Abassi1, Chamseddine Kifagi3, Myriam Fezai2, Renée Daams1, 
Florian Lang  2,4 & Ramin Massoumi1
Colorectal cancer is one of the most commonly diagnosed cancers and the third most common cause 
of cancer-related death. Metastasis is the leading reason for the resultant mortality of these patients. 
Accordingly, development and characterization of novel anti-cancer drugs limiting colorectal tumor cell 
dissemination and metastasis are needed. In this study, we found that the small molecule Reversine 
reduces the migration potential of human colon carcinoma cells in vitro. A coupled kinase assay with 
bio-informatics approach identified the c-Jun N-terminal kinase (JNK) cascade as the main pathway 
inhibited by Reversine. Knockdown experiments and pharmacological inhibition identified JNK1 but 
not JNK2, as a downstream effector target in cancer cell migration. Xenograft experiments confirm 
the effect of JNK inhibition in the metastatic potential of colon cancer cells. These results highlight the 
impact of individual JNK isoforms in cancer cell metastasis and propose Reversine as a novel anti-cancer 
molecule for treatment of colon cancer patients.
Colorectal cancer (CRC), a tumor on the inner lining of the rectum or colon is one of the most common cancers 
and a major cause of cancer-related death worldwide1,2. Despite substantial improvement in CRC diagnosis and 
therapy, the survival of CRC patients remains poor due to cancer cell metastasis3. Thus, development and charac-
terization of inhibitors counteracting CRC metastasis are needed.
The JNK pathway is one of the six distinct groups of MAPK (Mitogen-activated protein kinase)4. Three 
genes encode the family; Jnk1, Jnk2 and Jnk3. Jnk 1 and 2 are ubiquitously expressed, whereas Jnk3 expression 
is restricted to the brain, heart and testis5. JNK is activated in response to various extracellular stimuli, includ-
ing tumor necrosis factor (TNF), epidermal growth factor (EGF), platelet-derived growth factor (PDGF), trans-
forming growth factor β (TGF-β) and lysophosphatidic acid, as well as diverse environmental stresses6. The JNK 
pathway plays a key role in cell differentiation, inflammation and apoptosis4. Moreover, JNK is implicated in 
cell migration of several cell types6. The role of JNK signaling in CRC has been well documented recently with 
increasing evidence in support of up-regulated JNK activation in intestinal tumors. Indeed, activation of JNK in 
the intestine promotes cell proliferation7. Moreover, two well-known tumor suppressor genes; FBXW7 (F-box/
WD repeat-containing protein 7) and PDCD4 (programmed cell death 4) that can inhibit the activity of JNK, 
were shown to be inactivated in CRC8–10. Along those lines, pharmacologic inhibition of JNK reduced the growth 
of several adenocarcinoma cell lines7,11. Furthermore, JNK1/c-jun pathway is involved in multidrug resistance of 
colon cancer cells12.
In a previous work, we showed that two mitotic kinase inhibitors namely SP600125 and Reversine reduced 
the migration of soft tissue sarcoma cell lines13. SP600125 (anthra[1,9-cd]pyrazol-6-(2H)-one), a reversible 
ATP-competitive inhibitor of MAPK-JNK, was identified as direct inhibitor of JNK activity in a high throughput 
screening of a private chemical library held by Celgene14. SP600125 targets specifically JNK1, JNK2 and JNK3 
with an IC50 values of 40 nM for JNK1 and JNK2, as well as 90 nM for JNK314. SP600125 further inhibits the 
mitotic serine/threonine kinases Aurora kinase A and B15 and Monopolar spindle 1 kinase (Mps1)16,17. SP600125 
is widely used to disrupt signaling underlying diverse biological processes including inflammation, neurodegen-
eration, metabolic disease and cancer18.
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Reversine (2-(4-morpholinoanilino)-6-cyclohexylaminopurine) is a small molecule synthesized at Scripps 
Research Institute California in 2003 and was first used as a dedifferentiation agent19. Reversine reverses differ-
entiation of lineage-committed cells to mesenchymal stem cells (MSCs) allowing the cells to undergo differenti-
ation into other lineages20–22. Later, the role of Reversine in anti-tumor activities, including mitotic catastrophe, 
cell-cycle arrest, polyploidy and autophagy was discovered in several cancer cell lines23–27. Recently, Reversine was 
reported as an inhibitor of eryptosis, the suicide of erythrocytes28. Structurally, Reversine is an ATP analogue and 
inhibits cellular enzymatic activities29 of Monopolar spindle 1 (Mps1) kinase23,30,31, Aurora kinase A and B30–32 
and Akt/mTOR33,34.
In this study, we identified Reversine as a potent inhibitor of colon cancer cells migration and metastasis. The 
substance is effective by interference with JNK1-signaling.
Results
Reversine and SP600125 inhibit colon carcinoma cell migration. In a previous study, we developed 
a screening assay using the two dimensional OrisTM cell migration to target invasive sarcoma cell lines by treating 
with several mitosis and cytoskeleton inhibitors at 3 different doses (0.1, 1 and 10 μM) for 24 hours13. The aim of 
this test was to discover potent anti-migratory agent/s (≥50% as a cut off) without any major cell toxicity (≤30% 
of toxicity as limit) (Fig. S1). By calculating both the ratio of the field area and cells count of the migration zone 
it was found that Reversine and SP600125 at 10 μM prevent the migration of sarcoma cells13. Thus, we decided 
to investigate the effect of these molecules on the migration of the human colon carcinoma cell line RKO which 
are considered as one of the most invasive colorectal carcinoma cell lines35.
In a first experimental approach, we performed a wound-healing test and found that the decrease of cell free 
area was significantly delayed in the presence of SP600125 (55 +/− 0.7%) or Reversine (48 +/− 0.1%) (Fig. 1A). 
The two dimensional OrisTM cell migration assay confirmed the anti-migratory effect of Reversine and SP600125 
compared to solvent treated RKO cells (Fig. 1B), Reversine inhibited migration by 40 +/− 0.1% and SP600125 
by 37 +/− 0.1%. In addition, SP600125 and Reversine reduced individual cell migration, tracked by time laps 
microscopy (Fig. 1C). Moreover, using Boyden chamber assay, cell invasion was completely abolished in cells 
treated with Reversine and SP600125 for 24 h (Fig. 1D)
To exclude toxic effects of Reversine and SP600125, the RKO cells were treated with Reversine and SP600125 
for 24 hours and subsequently used for Flow Cytometry (FACS) analysis to assess cell death associated param-
eters. The cells were co-stained with the propidium iodide to check plasma membrane integrity, and Annexin 
V-FITC to measure cell membrane scrambling and phosphatidylserine translocation, which are used as a hall-
mark of apoptosis. Cell membrane scrambling and phosphatidylserine outer membrane exposure was similar in 
Reversine and SP600125 treated cells and DMSO-treated cells (Fig. 2A). Further, we used DiOC6(3), to measure 
the mitochondrial transmembrane potential (Δψm). Mitochondrial potential and cell membrane permeability 
were not significantly different between Reversine or SP600125 treated cells and DMSO treated cells (Fig. 2B). 
Moreover, cell cycle FACS analysis showed that subG1 fraction relative to DNA degradation was not signifi-
cantly different between SP600125 or Reversine treated cells and DMSO-treated cells (Fig. 2C). Together, these 
results suggest that 24 h treatment of colon cancer cells with Reversine and SP600125 does not affect cell death 
parameters. In parallel, we decided to investigate the cytotoxicity effect of Reversine and SP600125 treatment in 
non-cancerous cells including non-transformed fibroblast IMR90 and normal human colon mucosal epithelial 
cell NCM460 using the propidium iodide and DiOC6 staining. It was found that mitochondrial potential and 
cell membrane permeability were not different between treated and control cells (Fig. 2D). The evaluation of the 
subG1 fraction further confirmed this finding (Fig. 2E). Together, these results suggest that 24 h treatment of 
non-cancerous cells with Reversine and SP600125 does not affect cell death parameters.
To exclude any anti-proliferative effect of Reversine or SP600125 that may overlap with the anti-migration 
effect, several assays were performed. Crystal violet cell proliferation assay showed that Reversine and SP600125 
has no influence in cell proliferation after 24 h of treatment (Fig. 2F and Fig. S2). A contrario, treatment of cells 
with 200 ng/ml Nocodazole, which we used here as a potent anti-mitotic drug, showed a complete proliferation 
arrest (Fig. 2F). Next, we analyzed and compared the status of cell cycle in Reversine and SP600125 treated cells 
compared to DMSO. Treatment of cells Reversine and SP600125 continued to cycle and undergo polyploidy as 
well as exhibited histone H3 phosphorylation, which is a marker of ongoing cell mitosis (Fig. 2G). Altogether, this 
data together with our previous findings demonstrate that SP600125 and Reversine do not influence cancer cells 
proliferation at 24 h but instead induces cells polyploidization17,23.
Reversine and SP600125 target the JNK pathway. Reversine and SP600125 are reported as broad- 
spectrum inhibitors of serine/threonine kinases17,23. To identify the common target kinases of these small 
molecules, we decided to perform a kinase profiler screening36 (Fig. 3). Treatment of RKO cells with 10 µM of 
Reversine or SP600125 inhibited several kinases with varying efficiency. We selected kinases that were inhib-
ited more than 90%. As a result, in a panel of 222 kinases, SP600125 and Reversine inhibited 36 and 93 kinases, 
respectively. However, 22 kinases were inhibited by both drugs (Fig. 3B–C). Focusing on these 22 kinases, and to 
select the pathway involved in the anti-migration effect of SP600125 and Reversine, we choose a bio-informatics 
approach. Genes relative to the kinases list were used in enrichment analysis to identify over-represented gene 
ontology (GO) categories (Fig. S3).
Regulation of the JNK cascade exhibited the highest enrichment score (Term p-value after correction with 
Bonferroni = 1,42 × 10−6) for the common SP600125 and Reversine-inhibited kinase (Fig. 4A). The other top 
gene-sets were mitotic spindle organization, protein auto-phosphorylation, peptidyl-serine phosphorylation, 
and vascular endothelial growth factor (VEGF) signaling pathways (Fig. 4A–C). To confirm the role JNK in the 
migration process, we decided to investigate the expression and activation of JNK in the RKO cells compared 
to the normal human colon mucosal epithelial cell NCM460. It was found that JNK is highly expressed and 
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activated in the human colon cancer cells compared to the non-cancerous cells (Fig. 4D). Moreover, by checking 
the level of total JNK and phospho JNK in control vs. treated cells with Reversine or SP600125, we found that 
Reversine affect slightly the expression of JNK protein, particularly the levels of JNK1 (The lower band in the 
western corresponding to 46 KDa, Fig. 4E). Furthermore, Reversine or SP600125 treatment completely abolishes 
Figure 1. Reversine and SP600125 inhibit human colon carcinoma RKO cells migration. (A) Wound-
Healing assay. The human colon carcinoma RKO cell lines were plated in a 6-well plate and kept to monolayer 
confluence and then a wound-healing assay was performed. Representative photomicrographs are shown. The 
yellow broken lines delimit the cell-free area. Quantitative data of anti-migration % comparatively to control 
are presented in the right of the panel. (B) Two-dimensional migration assay using the Oris™ cell assay. Cells 
were allowed to migrate for 24 h after the removal of cell seeding stoppers and treatment, fixed and stained 
with phalloidin and DAPI to evaluate their motile potential. Representative photomicrographs are shown. The 
yellow broken lines delimit the cell-free area after 24 h of migration while the purple broken lines delimit the 
cell-free area at time 0 h. Quantitative data are presented in the right of the panel. (C) Individual cell tracking 
assay. Cells were grown in non-confluent conditions and imaged for 24 hours, using time-lapse microscopy, to 
evaluate respective migration potential of individual cells. Representative photomicrographs are shown with the 
trajectories reconstituted using Image J software of some cells with or without treatment. Quantitative data of 
cells speed are presented in the right of the panel. (D) Boyden chamber assay. Cells were collected, washed and 
suspended in free serum medium. Cells were then added to the upper compartments of the Boyden chamber in 
the presence or absence of Reversine or SP600125. Representative photomicrographs of cells that had migrated 
24 h later to the lower side of the filter are shown. Quantitative data are presented in the right of the panel. Data 
are reported in SEM; n = 3. ***(p < 0.001) indicates significant difference from the absence of Reversine or 
SP600125 treatment (ANOVA).
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the phosphorylation of JNK1/2. (Fig. 4E). Next, we investigated the downstream targets of JNK pathway upon 
Reversine treatment. Reversine decreased the expression of c-Fos and c-Jun, a direct target of JNK-mediated 
pathway (Fig. 4F)37. Interestingly, Reversine also inhibited activation of p38 but not ERK. We also evaluated the 
level of Akt activation (another player of cell migration)38 and confirmed the Reversine selectivity, a contrario of 
SP600125, for Akt39 (Fig. 4F).
Figure 2. Inhibition of migration by Reversine and SP600125 is not due to treatment toxicity.(A–C) The 
toxicity of Reversine and SP600125 at 24 h was evaluated by flow cytometry upon staining with the cell death–
associated parameters dyes. (A) Human colorectal carcinoma RKO cells were left untreated or treated for 24 h 
with 10 μM SP600125 or Reversine and then co-stained with the vital dye propidium iodide (PI) and the FITC-
conjugated Annexin V for the detection of phosphatidylserine exposure. Representative dot plot (SP600125 
treatment) and quantitative data are reported. White columns depict the percentage of dying cells (PI−Annexin 
V+) while black columns illustrate dead cells (PI+). (B) Cells were co-stained with the vital dye propidium 
iodide (PI) and the mitochondrial membrane potential (Δψm)-sensing dye DiOC6(3). Representative plot 
of SP600125 treated cells is shown and quantitative data are represented. White and black columns depict 
the percentage of dying (PI−DiOC6(3) low) and dead (PI+) cells, respectively. (C) RKO cells left untreated or 
exposed for 24 h with SP60015 or Reversine were fixed with ethanol and labeled with the DNA dye PI, for 
the quantification of the subG1 apoptotic population. Quantitative data are reported. (D–E) The toxicity of 
Reversine and SP600125 on non-cancer cells line. (D) Non transformed fibroblast IMR90 and normal human 
colon mucosal epithelial cell line NCM460 were left untreated or treated for 24 h with 10 μM SP600125 or 
Reversine and then co-stained with the vital dye propidium iodide (PI) and the mitochondrial membrane 
potential (Δψm)-sensing dye DiOC6(3). Quantitative data are represented. White and black columns depict 
the percentage of dying (PI−DiOC6(3) low) and dead (PI+) cells, respectively. (E) IMR90 and NCM460 cells left 
untreated or exposed for 24 h with SP60015 or Reversine were fixed with ethanol and labeled with the DNA dye 
PI, for the quantification of the subG1 apoptotic population. Quantitative data are reported. (F–G) Reversine 
and SP600125 do not affect cells proliferation and induces polyploidization. (F) Cells were seeded in 96 well 
plates and cultured for 24 h with or without treatment. Nocodazole at 200 ng/ml was used as positive control. 
Cell proliferation was assessed using crystal violet assay. Quantitative data are shown. Grey bar depict the 
optic density at 0 h while dark grey bar represent the optic density at 24 h, respectively. (G) Cells left untreated 
or exposed for 24 h with SP60015 or Reversine were fixed with ethanol and stained with an antibody specific 
for phosphorylated histone 3 (pH3), which is a mitosis-specific marker. Representative scatter plots and 
quantitative results of pH3 are shown. Numbers indicate the percentage of cells found in each quadrant. Data 
are reported in SEM; n.s indicates non-statistical difference from the control (ANOVA). *(p < 0.05) indicates 
statistical difference from the control. ***(p < 0.001) indicates statistical difference from the absence of 
Nocodazole treatment (ANOVA).
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Inhibition of JNK1 but not JNK2 reduces the migratory potential of colon carcinoma cells. 
Three kinases, JNK1 (MAPK8), JNK2 (MAPK9), and JNK3 (MAPK10), constitute the c-Jun N-terminal kinase 
family (JNK)40. In our study, we excluded JNK3 since it is mainly expressed in neurons, heart and testis. To distin-
guish between JNK1 and JNK2-mediated cell migration, we treated cells with a specific inhibitor of JNK2 (JNK 
inhibitor IX, Santa Cruz Biotechnology, Dallas, USA)41,42 and performed a wound-healing (Fig. 5A,B) as well as 
a two dimensional OrisTM cell migration assay (Fig. 5C,D). Wound recovering and migration zone invasion were 
similar after 24h-treatment with the JNK2 inhibitor and control treated cells. To confirm this data, we treated 
the cells with small interfering RNAs specific for JNK1 or JNK2. As depicted in Fig. 6A, RKO cells were trans-
fected with unrelated siRNA (siUNR), siJNK1/2, or siJNK2 in a 6-well plate for 24 h and condensed further into 
a 96-well plate. The efficacy of siRNA JNK1/2 and JNK2 were studies using Western blot analysis (Fig. S4). After 
the cells formed a monolayer, a scratch assay was performed, and cells migration was monitored by microscopy. It 
was evident that the decline of cell free area was significantly delayed following knockdown of JNK1/2 compared 
to siRNA UNR (74 +/− 0.4% of inhibition) or siJNK2-treated cells (Fig. 6B,C). To exclude toxic effect of JNK1 
and JNK2 knockdown, FACS analyses of the death related parameters were investigated. It was found that siRNA 
transfection of RKO cells with JNK1 or JNK2 did not induce any significant changes in the overall cell survival 
(Fig. 6D,E). Moreover, we analyzed the cell cycle of RKO after the knockdown of JNK1/2 and JNK2 and found 
that the siRNA transfection was not influencing cell cycle or cell proliferation (Fig. 6F).
The administration of SP600125 in vivo affects the metastasis of human colon carcinoma RKO 
cells. To evaluate the therapeutic and anti-metastatic potential of JNK inhibition in vivo, animals were injected 
intravenously with 2 × 106 RKO cells/mouse. The mice were treated intraperitoneally every 3 days with a con-
trol vehicle or 10 mg/kg SP600125 (Fig. 7A). The SP600125-treated mice showed fewer tumor metastases in the 
liver (Fig. 7B,C), lung (Fig. 7F,G), spleen, and kidney (Data non shown) compared with control-treated animals. 
Moreover, the average and ratio of liver weight compared to the body weight were higher in vehicle- compared 
to SP600125-treated mice (Fig. 7D,E). No differences could be observed in the average body weight compar-
ing vehicle and SP600125-treated mice (Fig. 7H). To further confirm the implication of JNK inhibition in vivo, 
we extracted the proteins from tumors isolated from lung and liver for western blotting. Densitometic analy-
sis demonstrated that SP600125 reduces phospho JNK level in treated lung and liver comparatively to control. 
(Fig. S5).
Discussion
Metastasis is the leading cause of cancer mortality including colon cancer, which is one of the most invasive and 
metastable tumors43. Thus, it is very important and urgent to develop anti-cancer drugs to reduce tumor cells 
dissemination. Here, we report the identification of the small molecules Reversine and SP600125, which can 
interfere with JNK signaling, as inhibitors of migration and metastasis of colon carcinoma cells. In our study, we 
decided to use the primary colon cancer RKO cell line which harbors the microsatellite instability (MSI) pheno-
type and represents 15% of all CRCs. RKO cells harbor mutations in KRAS, BRAF, PIK3CA and PTEN and are 
considered as one of the most invasive colon cancer cell lines44.
Figure 3. Identification of Reversine and SP600125 common targets. (A–C). A kinase profiler screen of cells 
treated with 10 μM Reversine (Rev) or 10 μM SP600125 (SP) was analyzed. The heat map in panel (A) shows 
the residual kinase activity (% of control). The scale ranges from 0% (blue) to 100% (red). The Venn diagram in 
panel (B) displays the proteins that were inhibited more than 90% by either 10 μM of Reversine or SP600125. 
The 22 common target proteins are listed in panel (C).
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We took advantage of a novel screen assay, using the two dimensional OrisTM cell migration developed in a 
previous study13. The previous test revealed Reversine and SP600125 as potent anti-migratory drugs of invasive 
sarcoma cells. In the present study, we explored the effect of Reversine and SP600125 on the human colon car-
cinoma RKO cells. We exposed cells for 24 h to both small molecules and found that this treatment significantly 
delayed the migration and invasion of RKO cells using different assays, namely wound-healing, two dimensional 
OrisTM assay, individual cell tracking assay, and Boyden chamber assay. The anti-migratory effect of these drugs 
was not due to toxicity or cell apoptosis. Moreover, the treatment did not affect cell proliferation at 24 h, which 
is in line with our previous findings17,23. In this work we could also show that 24 h treatment with Reversine 
or SP600125 is non-toxic to the non-cancerous cells including non-transformed fibroblast and human colon 
mucosal epithelial cells. The kinase profiler screening identified several kinases that were inhibited by both 
Reversine and SP600125. This result in combination with bio-informatics (GO: gene ontology) approaches iden-
tified the JNK family activation as the most significant pathway inhibited by Reversine and SP600125. To distin-
guish between JNK1 and JNK2 activation, RKO cells were treated with specific siRNAs targeting JNK1/2 or JNK2, 
as well as treatment with a specific JNK2 inhibitor. The results demonstrated that only JNK1 inhibition delays 
the motility of these cells. Western blot analysis showed that JNK is overexpressed and activated in RKO cancer 
cells compared to normal colon mucosal epithelial cells. We could also show that Reversine, similar to SP600125, 
reduces the activation and expression of JNK in treated cells. Additionally, we demonstrate that activation of JNK 
related signaling pathway proteins including c-Fos, c-Jun, and p38 but not ERK were significantly decreased with 
Reversine treatment. The specificity of Reversine but not SP600125 could be observed against the activation of 
AKT, which is in line with previous finding39.
Reversine is a specific inhibitor of the human mitotic kinase Mps130, whereas SP600125 is a well-known inhib-
itor for JNK1/214. Reversine inhibits Mps1 in vitro with an IC50 of 63 nM45, whereas SP600125 targets Mps1 with 
an IC50 of 1.95 µM and JNK with an average of 56 nM (JNK1, 2 and 3)16. Previous studies could show that Mps1 
Figure 4. The JNK cascade is the principal pathway inhibited by Reversine and SP600125. (A–C) Gene 
Ontology analysis of the common target genes (22) of Reversine and SP600125 was done by the Cytoscape 
associated-plugin ‘ClueGO’. ‘Positive regulation of JNK cascade’ was the most associated term with both 
Reversine and SP600125 (A). Network view of target genes of Reversine and/or SP600125 was performed 
by Cytoscape and GeneMANIA associated-plugin. Red colors represent the inhibited proteins through the 
Kinase panel test and JNK related nodes were highlighted in green zones after Reversine (B) and SP600125 
(C) treatment. (D) Overexpression and activation of JNK was investigated in RKO colon cancer cell line 
comparatively to the normal human colon mucosal epithelial cell line NCM460. (E) Inactivation of JNK by 
SP600125 or Reversine in RKO cells was confirmed by Western blot. (F) Downstream targets of JNK pathway 
after treatment with Reversine or SP600125 were checked by western blot.
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and JNK have a high degree of sequence similarity in their ATP-binding pocket16,46. Mutation of methionine 
M108 to glutamine in JNK1 renders it insensitive to SP600125 inhibition47. Moreover, the corresponding muta-
tion in Mps1 (M602Q) also proved significantly less sensitive to SP60012516,17. These results in combination with 
our findings suggest that Reversine and SP600125 share the common target kinase JNK.
It is becoming increasingly clear that JNK1 is essential for cell migration. In the present study, we found 
that treatment with SP600125 of intravenously injected tumor cells reduces liver and lung tumor metasta-
ses. This effect is in line with previous findings that showing the same effect upon treatment of animals with 
Reversine48. Several studies investigated the effect of JNK1 inhibition by chemicals, small interfering RNA, or 
dominant-negative mutant, and could confirm the role of JNK-signaling in migration of several different cell 
types. In these studies, the overexpression of a dominant-negative mutant of JNK1 reduced the migration of rat 
urinary bladder NBT-II cells49, cortical neurons50, human umbilical vein endothelial cells51, and bovine aortic 
endothelial cells52. Moreover, JNK1 siRNA transfection delays the migration of gastric cancer cells53, mouse hepa-
tocellular carcinoma cells54, and human melanoma cells55. Furthermore, JNK inhibitors were vastly employed to 
inhibit migration in several cell lines including human dermal fibroblasts56, smooth muscle cells57, murine corti-
cal neuronal cells50, schwann cells58, murine epidermal keratinocytes, murine dermal fibroblasts59, thyroid cancer 
cells60 uterine luminal epithelial cells61 and human lung adenocarcinoma cells62.
The JNK signaling is implicated in cell scattering during epithelial-to-mesenchymal transition (EMT) in pul-
monary epithelial cells63. Moreover, JNK1 is an important regulator of cell-cell adhesion. Indeed, the epithelial 
tight junctions (TJ) and adherent junctions (AJ) reassembly is accelerated by JNK1 but not by JNK2 inhibi-
tion, leading to changes in epithelial morphology and migration delay64. In addition, cytoskeletal proteins are 
important JNK substrates, including proteins associated with the microtubules (DCX, MAP1B, MAP2, Tau and 
WDR62), proteins associated with the actin cytoskeleton (MARCKSL1 and SMTL2), and focal adhesion pro-
teins (paxillin and β-catenin)65. Moreover, recent studies have connected additional JNK target proteins to the 
cytoskeleton control, including actin filament assembly proteins (Formin1, FHOD3), microtubule-associated 
proteins (CCSER1), and molecular motors (Myosin-9B). However, these important processes remain largely lim-
ited and further studies are needed to explore the mechanism65.
In cancer, JNK is widely documented as implicated in several tumors including melanoma, head and neck, 
breast, ovarian and gastric cancers, suggesting that JNK may be an attractive target for cancer therapy66. However, 
it has also been proposed that JNK1 and JNK2 have different specific cellular targets in cancer and thus the mech-
anisms involving individual JNK proteins is generally unknown. In the present study we could provide evidence 
Figure 5. Specific inhibition of JNK2 does not affect the migratory potential of the human colon carcinoma 
RKO cells. (A,B) Wound-Healing assay. The human colon carcinoma RKO cell was plated in a 6-well 
plate and kept to monolayer confluence and then a wound-healing assay was performed. Representative 
photomicrographs are shown in panel (A), the yellow broken lines delimit the cell-free area. Quantitative data 
of anti-migration % comparatively to control are presented in panel (B). (C,D) Two-dimensional migration 
assay using the Oris™ cell assay. Cells were allowed to migrate for 24 h after the removal of cell seeding stoppers 
and treatment, fixed and stained with phalloidin and DAPI to evaluate their motile potential. Representative 
photomicrographs are shown in panel (C), the yellow broken lines delimit the cell-free area after 24 h of 
migration. Quantitative data are presented in panel (D). (E) The toxicity of JNK2 inhibitor was evaluated by 
flow cytometry upon staining with the vital dye propidium iodure (PI) and the mitochondrial membrane 
potential (Δψm)-sensing dye DiOC6(3). Data are reported in SEM; n = 3. n.s indicates non-statistical 
difference from the control (ANOVA).
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that JNK1 but not JNK2 promotes migration and metastasis of colon carcinoma cells and that Reversine inhibits 
migration of the cells by modulating the JNK signaling pathway.
Materials and Methods
Cell lines, culture conditions and reagents. Human colon carcinoma RKO cells were grown in McCoy’s 
5 A medium supplemented 10% fetal calf serum (FCS), 10 mM HEPES buffer, 100 units/mL penicillin G sodium 
and 100 μg/mL streptomycin sulfate. IMR90 human fibroblast cells were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10% fetal calf serum (FCS) and 100 units/mL penicillin G sodium. 
NCM460 cells were maintained in INCELL’s enriched M3:10 medium (M310A; which is M3 Base medium plus 
supplements with 10% FBS and contains antibiotics). Cell lines were routinely maintained at 37 °C under 5% CO2. 
Figure 6. Inhibition of JNK1 and not JNK2 reduces the migratory potential of the human colon carcinoma 
RKO cells. (A–C) Cells were seeded into 6-well plate and were transfected with an unrelated small interfering 
(si) RNA (siUNR) or specific siRNAs directed against JNK1/2 or JNK2 (siJNK1/2 and siJNK2) (two well per 
condition). Upon 24 h, cells were harvested and seeded in a 96-well plate to ensure a monolayer confluence. 
After overnight culture a wound-healing test was performed and migration was evaluated after 24 h. 
Representative photomicrographs are shown in panel (B), the yellow broken lines delimit the cell-free area. 
Quantitative data of anti-migration % comparatively to control are presented in panel (C). (D-E) The toxicity 
of siRNAs JNK1/2 or JNK2 was evaluated by flow cytometry upon staining with the cell death–associated 
parameter dyes. RKO cells were transfected with siUNR, siJNK1/2 or siJNK2 for 48 h and then co-stained with 
the vital dye propidium iodide (PI) and the FITC-conjugated Annexin V for the detection of phosphatidylserine 
exposure (D) or co-stained with the vital dye propidium iodide (PI) and the mitochondrial membrane potential 
(Δψm)-sensing dye DiOC6(3) (F). Cells were transfected with siUNR, siJNK1/2 or siJNK2 for 48 h and 
then fixed with ethanol and labeled with the DNA dye PI, for the quantification of cell cycle. Representative 
histograms are shown. Data are reported in SEM; n = 3. ***(p < 0.001) indicates significant difference from the 
siUNR transfection (ANOVA).
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Reversine (BioNordika, Stockholm, Sweden), SP600125 (Sigma-Aldrich), Nocodazole (Sigma-Aldrich) and JNK 
inhibitor IX (Santa Cruz Biotechnology, Dallas, USA) were stocked as 10 mM solution in DMSO.
Migration and Invasion assays. 
i  For wound-healing assay, scratches were performed on confluent cell monolayers with sterile 200 μl tips and 
monitored every 12 h by microscopy. Migration distances were expressed as percentages over control values. 
Indeed, as the scratches are not equal at time 0, we normalized the values by dividing every value by the time 
0 value in every condition (Remaining free area/free area time 0).
ii  The two dimensional OrisTM cell migration assays were performed according to the manufacturer’s instruc-
tions (Platypus Technologies, Madison, USA). Briefly, cells were seeded (4 × 104 cells per well) into 96-well 
plates with “silicone stopper” and grown overnight. Then stoppers were removed, and cells were incubated 
for an GraphPad Prism using ANOVA with Tukey’s test as post-hoc and T-test (for the animal experiments).
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